Clinical trials: Gram-negative Bacteraemia
Gram-negative Bacteremia, Bloodstream Infection
Fast Antibiotic Susceptibility Testing for Gram Negative Bacteremia Trial
This study is a 2-arm, multicenter, multinational, prospective, randomized, controlled clinical trial. Hospitalized subjects with blood cultures growing Gram negative bacilli (GNB) will be randomized 1:1 to have the positive…
- Trial name
- FAST (NCT06174649)
- Testing
- Reveal
- Where
- 7 sites in Greece, India and 2 more
- Volunteers
- 899 people
- Sponsor
- Duke University
Allogeneic or Autologous HSCT
Gram-negative Bacteremia in HSCT Recipients
A significant increase in resistant bacteria emerging in HSCT recipients. For example, 25% - 42% of all enterobacteriaceae produce extended spectrum beta-lactamases; 8 - 72% of Pseudomonas aeruginosa are resistant to at least one…
- Trial name
- GNB (NCT02257931)
- Where
- 10 sites in Belgium, China and 7 more
- Volunteers
- 591 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Infections, Streptococcal
A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants
The primary aim of the study is to demonstrate that an investigational 4-dose presentation of the 10Pn-PD-DiT vaccine with preservative is non-inferior to the licensed presentation of Synflorix (preservative-free) in terms of…
- Trial name
- NCT02447432
- Testing
- Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation), Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation), DTPw-HBV/Hib
- Where
- Bangladesh
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Enterobacteriaceae Infections, Bacteremia
Infections Caused by ESbL-Producing Enterobacteriaceae in Italy
To assess the molecular epidemiology, clinical impact, treatment outcome and risk factors for infections caused by Enterobacteriaceae producing ESBLs in Italy in a large multicenter observational survey. SPECIFIC OBJECTIVES 1.
- Conditions
- Enterobacteriaceae Infections, Bacteremia, Pneumonia, Skin Diseases
- Trial name
- NCT00404625
- Testing
- Risk factors for infections due to ESBL+ Enterobacteriaceae, Risk factors for inadequate initial antimicrobial therapy, Overall and 30-day mortality in bad first antibiotic therapy
- Where
- 6 sites in Italy
- Volunteers
- 813 people
- Sponsor
- University of Siena
Gram-negative Bacteremia
Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia
RAPIDS-GN is a multi-center, prospective, randomized, controlled trial to evaluate the following strategies for patients with confirmed gram-negative bacillus bacteremia (GNB): 1.
- Trial name
- RAPIDS-GN (NCT03218397)
- Testing
- Accelerate PhenoTest™ BC Kit, Standard Culture and AST
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- Duke University
Campylobacter Infections
Recurrent Campylobacter Bacteraemia in Immunocompromised Patients
Some rare cases of recurrent Campylobacter bacteraemia (RCB) exist with relapses months to years after an effective treatment and a negativation of all bacterial samples.
- Trial name
- CABARET (NCT06432777)
- Testing
- Characteristics of patients and Campylobacter bacteraemia episodes
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Bacteremia, Enterobacteriaceae Infections
Ultra Rapid Culture Independent Detection of High-Priority Carbapenem Resistant Enterobacteriaceae Directly From Blood
The purpose of this study is to develop a new and very rapid diagnostic test for identifying a certain type of bacteria called Enterobacteriaceae in blood.
- Trial name
- NCT02482051
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Denver Health and Hospital Authority
Gram-negative Bacteremia
BALANCE+ Vanguard Phase
The goal of the BALANCE+ clinical trial is to transform random care to randomized care for patients with Gram negative bloodstream infections to inform best treatment approaches and optimize outcomes.
- Trial name
- BALANCE+ (NCT05893147)
- Testing
- De-escalation VS No De-escalation, Oral beta-lactams VS non beta-lactams, Central vascular catheter retention VS Central vascular catheter replacement
- Where
- 10 sites in Canada
- Volunteers
- 174 people
- Sponsor
- Sunnybrook Health Sciences Centre
Gram-negative Bacteremia
A Platform Trial for Gram Negative Bloodstream Infections
BALANCE+ is a perpetual multiple domain randomized controlled platform trial to evaluate various treatment strategies for Gram-negative bloodstream infections (GN BSIs).
- Trial name
- BALANCE+ (NCT06537609)
- Testing
- De-escalation VS No De-escalation, Oral beta-lactams VS non beta-lactams, Central vascular catheter retention VS Central vascular catheter replacement
- Where
- 39 sites in Australia, Canada and 3 more
- Volunteers
- 2,500 people
- Sponsor
- Sunnybrook Health Sciences Centre
Acinetobacter Infections
Impact of Treatment With Colistin on Mortality Bacteremia Multiresistant Acinetobacter Baumannii Sensitive Colistin in Patients Critical
The present study was designed to study the impact of empirical treatment with colistin empirical monotherapy and combined treatment with tigecycline and vancomycin on mortality of bacteremia Multiresistant Acinetobacter…
- Trial name
- NCT02573064
- Testing
- Colistin, Tigecycline, Vancomycin
- Volunteers
- 113 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba